D-MELD risk capping improves post-transplant and overall mortality under markov microsimulation

Figure 1 Schematic of Markov model states and transitions. MELD: Model for End-Stage Liver Disease.

Figure 2 Model for End-Stage Liver Disease subgroups. A: Percentage of patients remaining waitlisted at initial Model for End-Stage Liver Disease over time; B: Analysis of patient movement between subgroups for those remaining waitlisted at 90 d. MELD: Model for End-Stage Liver Disease.

Figure 3 Comparison of actual data to model, overall and post transplant survival for all patients. A: Overall; B: Post transplant.

Figure 4 Comparison curve. A: Overall survival is subgrouped by MELD at listing. Comparison of actual data vs model; B: Post transplant survival subgrouped by MELD at transplantation. Comparison of actual data vs model. MELD: Model for End-Stage Liver Disease.

Figure 5 Comparison of post transplant survival between current modeled survival and Model for End-Stage Liver Disease score excluding exception points and donor age risk caps of 1200 vs 1600. Comparison is demonstrated for MELD subgroups at transplant and for all patients. MELD: Model for End-Stage Liver Disease; D-MELD: MELD score excluding exception points and donor age.

Figure 6 Model for End-Stage Liver Disease distribution at transplantation comparing modeled (current) vs proposed changes. MELD: Model for End-Stage Liver Disease; D-MELD: MELD score excluding exception points and donor age.

Figure 7 Likelihood of transplantation by Model for End-Stage Liver Disease subgroup at listing with comparison between current (modeled) vs proposed changes. MELD: Model for End-Stage Liver Disease; D-MELD: MELD score excluding exception points and donor age.

Figure 8 Overall survival for waitlisted patients subgrouped by initial Model for End-Stage Liver Disease at listing and all patients. MELD: Model for End-Stage Liver Disease; D-MELD: MELD score excluding exception points and donor age.